What is Shandong Weigao Blood Purification Products Co FCF Yield %?
Shandong Weigao Blood Purification Products CoSHSE:603014 +1.45%38 FCF Yield % is 4.05 as of Jul. 10, 2026, which is 11% above its 10-year median of 3.65. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 75.91% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
SHSE:603014's FCF Yield % is ranked better than 75.91% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.39
vs SHSE:603014: 4.05
Shandong Weigao Blood Purification Products Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shandong Weigao Blood Purification Products Co FCF Yield % Related Terms
Shandong Weigao Blood Purification Products Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co FCF Yield % Chart
Shandong Weigao Blood Purification Products Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co FCF Yield % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a FCF Yield % of 4.05 as of Jul. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. This is 11% above median its historical median of 3.65. Over the past decade, Shandong Weigao Blood Purification Products Co's FCF Yield % has ranged from 2.99 to 4.48. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #206 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Shandong Weigao Blood Purification Products Co's FCF Yield % too high?
Shandong Weigao Blood Purification Products Co's current FCF Yield % of 4.05 is 11% above median its 10-year median of 3.65. Over the past 10 years, this metric has ranged from a low of 2.99 to a high of 4.48. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #206 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #206 out of 855 companies for FCF Yield %. This places Shandong Weigao Blood Purification Products Co in the top 24% of its industry — outperforming the majority of peers. Historically, Shandong Weigao Blood Purification Products Co's own FCF Yield % has ranged from 2.99 to 4.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. Shandong Weigao Blood Purification Products Co's current FCF Yield % is 4.05, which is 11% above median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current FCF Yield % of 4.05. The current FCF Yield % is 4.05, which is 11% above median its 10-year median of 3.65. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current FCF Yield % is 4.05 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shandong Weigao Blood Purification Products Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
